SQUAWK/NEWS
Account
Theme
Account
Menu
Live News REGULATION FLASH M impact

Roivant announces FDA approval and U.S. availability of LISRAYA

Roivant Sciences announced FDA approval and U.S. availability of LISRAYA for dermatomyositis.

ROIV

This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.